Literature DB >> 2959633

Human urinary excretion of doxifluridine and metabolites during a 5-day chemotherapeutic schedule using fluorine-19 nuclear magnetic resonance spectrometry.

M C Malet-Martino1, P Servin, J Bernadou, J P Armand, R Martino.   

Abstract

The urinary excretion of doxifluridine (5'dFUrd) and its metabolites was determined during five days of chemotherapy using fluorine-19 nuclear magnetic resonance spectrometry. The daily urinary excretion of 5'dFUrd and its metabolites was high (congruent to 100% of the 5'dFUrd administered) and nearly constant throughout the treatment. By far the major excreted compounds were unchanged 5'dFUrd and alpha-fluoro-beta-alanine which made up respectively congruent to to 40% and congruent to to 50% of the total. Neither accumulation of 5'dFUrd nor significant modifications in its metabolism were observed during the treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2959633     DOI: 10.1007/bf00175298

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  17 in total

1.  Studies on fluorinated pyrimidines. IX. The degradation of 5-fluorouracil-6-C14.

Authors:  K L MUKHERJEE; C HEIDELBERGER
Journal:  J Biol Chem       Date:  1960-02       Impact factor: 5.157

2.  Phase II study of oral administration of 5'-deoxy-5-fluorouridine (5'-DFUR) for solid tumors.

Authors:  E Shimizu; N Saijo; K Eguchi; T Shinkai; K Tominaga; Y Sasaki; J Fujita; H Nomori; A Hoshi
Journal:  Jpn J Clin Oncol       Date:  1984-12       Impact factor: 3.019

3.  Metabolism and biological activity of 5'-deoxy-5-fluorouridine, a novel fluoropyrimidine.

Authors:  R D Armstrong; R B Diasio
Journal:  Cancer Res       Date:  1980-09       Impact factor: 12.701

4.  Phase II study of 5'-deoxy-5-fluorouridine (doxifluridine) in advanced malignant melanoma.

Authors:  P Alberto; M Rozencweig; M Clavel; P Siegenthaler; F Cavalli; S Gundersen; U Bruntsch; J Renard; H Pinedo
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Complete urinary excretion profile of 5-fluorouracil during a six-day chemotherapeutic schedule, as resolved by 19F nuclear magnetic resonance.

Authors:  J Bernadou; J P Armand; A Lopez; M C Malet-Martino; R Martino
Journal:  Clin Chem       Date:  1985-06       Impact factor: 8.327

6.  19F nuclear magnetic resonance analysis of the carbamate reaction of alpha-fluoro-beta-alanine (FBAL), the major catabolite of fluoropyrimidines. Application to FBAL carbamate determination in body fluids of patients treated with 5'-deoxy-5-fluorouridine.

Authors:  R Martino; M C Malet-Martino; C Vialaneix; A Lopez; M Bon
Journal:  Drug Metab Dispos       Date:  1987 Nov-Dec       Impact factor: 3.922

7.  Neurological manifestations in a phase 2 study of 13 patients treated with doxyfluridine.

Authors:  M S Heier; S D Fosså
Journal:  Acta Neurol Scand       Date:  1985-08       Impact factor: 3.209

8.  Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study.

Authors:  S D Fosså; O Dahl; R Hoel; M Heier; M Loeb
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  Phase I clinical study with 5'-deoxy-5-fluorouridine, a new fluoropyrimidine derivative.

Authors:  R Abele; P Alberto; R J Seematter; G Germano; R Heintz; W Bollag
Journal:  Cancer Treat Rep       Date:  1982-06

10.  Phase II clinical evaluation of doxifluridine.

Authors:  P Hurteloup; J P Armand; P Cappelaere; R Metz; P Kerbrat; R Keiling; P Fumoleau; P Fargeot; S Schraub; P Bastit
Journal:  Cancer Treat Rep       Date:  1986-06
View more
  2 in total

Review 1.  Mass balance studies, with a focus on anticancer drugs.

Authors:  Jan H Beumer; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

Review 2.  Uses and limitations of nuclear magnetic resonance (NMR) spectroscopy in clinical pharmacokinetics.

Authors:  M C Malet-Martino; R Martino
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.